SPONSOR
Xiangdong Cheng
Total Trials
2
Recruiting
2
Phases
Phase 2
Conditions studied: Immune SuppressionGastric CancerAdvanced Gastric CarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma
Clinical Trials by Xiangdong Cheng
NCT05739045 Phase 2
Recruiting
Nivolumab Combined With SOX Used in the Perioperative Treatment
Immune Suppression
NCT06642857
Recruiting
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
Advanced Gastric Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology